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By the end of this decade, the baby boomer generation will 
be progressing well into their 60s. As this aging population 
rises, so, too, will the incidence of age-related 
neurodegenerative diseases. The demand for geriatric care 
will begin to rise, putting a strain on healthcare for the 
elderly, space available in care facilities, and family 
members. These diseases such as Alzheimer’s, Parkinson’s, 
and amyotrophic lateral sclerosis (ALS or Lou Gherig’s 
Disease), are still all incurable and fatal diseases. 
Parkinson’s Disease (PD) is caused by the death of a 
specific set of midbrain neurons that control voluntary 
movement. The accumulation of a misfolded form of the α-
synuclein protein into structures called Lewy Bodies may be 
one toxic agent involved in the pathogenesis of the disease. 
Four exciting new studies have modeled the misfolding of α-
synuclein in yeast. Examining this protein in other cellular 
systems may shed light on its toxic effects, bringing 
researchers closer to finding a cure. 
In order to gain more insight into α-synuclein’s role 
in PD, the protein has been expressed in several model 
organisms, such as Drosophila, C. elegans, and mice (1). 
One recent model used for α-synuclein expression has been 
the simple, easily manipulated, eukaryotic organism, yeast. 
Although yeast cells are vastly different from brain cells, 
there are actually many similarities in the way both 
eukaryotic cells conduct protein folding process and the way 
they maintain quality control over their own proteins. Outeiro 
et al. first reported α-synuclein expression in baker’s yeast in 
2003 (2), and the organism has since proven to be a widely 
used expression system. Three different laboratories have 
published their findings on α-synuclein expression in yeast in 
the two years thereafter. In comparing the most recent 
studies, much in vivo evidence is revealed about the 
protein’s lipid binding abilities, aggregation, and toxicity.  
 Identifying α-synuclein’s localization in a 
eukaryotic cell such as yeast may suggest how the protein 
interacts in other eukaryotic cells, specifically neurons. 
Perhaps the most consistent finding among the studies has 
been the way in which α-synuclein localizes within baker’s 
yeast. Each group tagged α-synuclein to a green fluorescent 
protein (GFP) in order to visualize the localization of the 
protein within the cells. They observed that wild-type (WT) α-
synuclein and the A53T familial mutant localized to the 
plasma membrane, while the A30P familial mutant was 
diffuse in the cytoplasm (3,4,5). This finding is consistent 
with a number of studies that have reported the protein’s 
lipid and membrane binding abilities. One group reported 
that a double A30P/A53T mutant displayed both membrane 
localization and diffuse cytoplasmic fluorescence (4). Two of 
these yeast studies found that by increasing expression time 
(3,5), the WT form of the protein lost membrane localization 
and accumulated within the cytoplasm.  
Determining the nature of this α-synuclein 
aggregation may give insight as to how the protein is 
involved in the pathogenesis of PD, a notion that is still not 
completely understood. In vitro studies have shown that α-
synuclein aggregation is a nucleation-dependent process 
(6); that is, the protein will aggregate further if a seed of  the 
 
*This paper was written for BIO493 Independent study taught by Dr. Shubhik 
DebBurman. 
 
 
 
protein is first formed. This seed formation, first described for 
an aggregation-prone amyloid bacterial protein in an 
Alzheimer’s study, is dependent upon 1) the initial 
concentration of the protein, and 2) the amount of time the 
protein is present in the system (7). To test this hypothesis 
for α-synuclein in vivo, GFP-tagged α-synuclein was 
expressed in fission yeast, a system with a set of vectors 
that produce various amounts of the protein. A very different 
phenotype from baker’s yeast was observed in fission yeast: 
there was no α-synuclein localization to the plasma 
membrane of fission yeast at any time point during its 
expression. WT and the A53T mutant formed foci within the 
cytoplasm, while A30P and the double mutant remained 
diffuse. Furthermore, by increasing expression time or by 
increasing protein expression levels, WT and A53T α-
synuclein displayed greater foci formation. This data is the 
first in vivo study that supports a time and concentration 
dependent process of α-synuclein aggregation (8).  
One of the baker’s yeast studies also revealed that 
α-synuclein aggregation is a nucleation-elongation process 
(5). This study showed that when A30P, which did not form 
inclusions upon expression by itself, formed aggregates 
upon coexpression with WT α-synuclein. Zabrocki et al. 
suggest that the A30P mutant forms inclusions on the nuclei 
of WT α-synuclein, and that on its own, A30P is defective in 
nucleation. This supports previous in vitro studies which 
demonstrate that A30P does not aggregate as easily as 
other forms of α-synuclein.  
Whether or not aggregated α-synuclein causes the 
neuronal death in Parkinson’s Disease patients is still a 
debated issue in the field. Each study conducted growth 
analyses to determine if α-synuclein was toxic to yeast cells 
in order to shed light on the problem. Only one of the three 
baker’s yeast studies found that α-synuclein, by itself, was 
toxic to wild type yeast strains (3). WT and A53T α-synuclein 
was toxic when expressed at increased levels, whereas 
A30P α-synuclein was not. The fission yeast study did not 
find α-synuclein to be toxic at any level of expression (8). All 
of the baker’s yeast studies, however, found that the protein 
was toxic if the yeast were compromised in certain ways that 
may be similar to how neurons are compromised in PD 
patients. For example, one study revealed that when α-
synuclein was coexpressed with the Alzheimer’s protein, tau, 
the combination was toxic to yeast (5); this is a lethal 
combination in some forms of PD and several other 
neurodegenerative conditions (9). Another group found that 
the expression of α-synuclein in yeast cells lacking an 
antioxidant enzyme, manganese superoxide dismutase, 
caused toxicity, and more so when cells were treated with 
hydrogen peroxide (4). This is consistent with the theory that 
oxidative stress conditions in midbrain neurons contribute to 
the onset of PD. Two studies expressed α-synuclein in yeast 
cells with proteasomal mutations; the proteasome is a 
structure that degrades α-synuclein, and if it were 
dysfunctional, the build-up of possibly toxic α-synuclein 
species might occur. Moreover, a defective proteasome has 
been linked to the pathogenesis of PD as one inherited form 
of the disease is caused by a mutation in the proteasomal 
pathway (10). These two studies, however, observed 
different results: Dixon et al. found α-synuclein to be toxic to 
cells a 20S proteasome barrel mutation (3), while Sharma et 
al. only found delayed α-synuclein synthesis and membrane 
localization (4).  
The most consistent findings among all these 
studies are that A30P is expressed diffusely in the cytoplasm 
and that α-synuclein localizes to the plasma membrane of 
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Table 1: Summary of the four studies’ notable findings.  
Although variation exists among these studies, it is important to note the consistency of plasma membrane localization and the A30P phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
baker’s yeast (see table). Only one study, however, showed 
that α-synuclein was toxic to yeast when expressed on its 
own. Although many other assays were conducted in these 
studies and although variation exists among these studies’ 
findings (see table), the results are consistent with many 
theories in the field, indicating that yeast may be a good 
model organism for examining α-synuclein activity. 
Moreover, a knockout for every gene in the baker’s yeast 
genome exists, which allows for quick evaluation of genes 
that may protect against α-synuclein toxicity. A study 
preliminarily conducted this evaluation and revealed eighty-
six knockout strains that were toxic upon α-synuclein protein 
expression (11). Further evaluation of these baker’s yeast 
knockout strains may reveal much more about α-synuclein’s 
cellular activity—information that can then be applied to its 
activity in neurons. In addition, the fission yeast model for α-
synuclein expression provides a good model for α-synuclein 
misfolding and aggregation. Although fission yeast has not 
been as widely used to model neurodegenerative diseases, 
it may in the future serve as an even better tool to study α-
synuclein misfolding when more knockout strains become 
available. These studies on yeast may promote the 
organism’s use for the modeling of other protein misfolding, 
neurodegenerative diseases—a group of diseases that 
plague, unfortunately, a significant portion of the world’s 
aging population. 
 
Note: Eukaryon is published by students at Lake Forest 
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